Cholangiocarcinoma, also called bile duct cancer, starts in the thin tubes that carry digestive fluid from your liver to your small intestine. It's rare and often found at an advanced stage because early symptoms can be mild or easy to miss. Treatment choices have traditionally been limited after a first round of chemotherapy stops working.
That's starting to change for a subset of people whose tumors carry a specific genetic change. Lyrfigtu (lirafugratinib) is a once-daily pill that targets a protein called fibroblast growth factor receptor 2 (FGFR2). The FDA approved Lyrfigtu in September 2026 for adults with previously treated cholangiocarcinoma whose tumors have an FGFR2 gene fusion or other rearrangement.
This article covers how Lyrfigtu works, who it's approved for, how it's taken, and what clinical studies have shown so far. You may also want to read about Lyrfigtu side effects and interactions.
How Does Lyrfigtu Work for Cholangiocarcinoma?
FGFR2 is a protein that sits on the surface of cells and helps send signals that tell cells when to grow and divide. In a small number of people with cholangiocarcinoma, a piece of the FGFR2 gene breaks off and joins with another gene, creating what's called a fusion (or feta rearrangement). This change can cause FGFR2 to send growth signals constantly, even when the body doesn't need new cell growth, which can fuel tumor growth.
Lyrfigtu is designed to attach tightly and permanently to FGFR2, shutting down the nonstop signal that drives cancer growth. Because it binds this way, it may also work against some resistance mutations. These mutations can make other FGFR2-targeted drugs less effective over time. Lyrfigtu selectively targets FGFR2 while sparing closely related proteins (FGFR1, FGFR3, and FGFR4), which may help limit certain side effects.
Is Lyrfigtu Right for Me?
Lyrfigtu is approved for adults with previously treated, unresectable (not removable with surgery), locally advanced, or metastatic bile duct cancer that carries an FGFR2 gene fusion or other rearrangement.
Two things generally need to be true before your health care provider considers Lyrfigtu:
- Your tumor has already been treated with at least one other systemic therapy (such as chemotherapy), and that treatment is no longer working or is no longer an option.
- Genetic testing of your tumor shows an FGFR2 fusion or other rearrangement, and you haven't previously been treated with a different FGFR inhibitor medicine.
Before you start Lyrfigtu, your health care provider will order testing on a tumor sample to look for this genetic change. This is sometimes called biomarker or molecular testing, and it's a required step. Not everyone with cholangiocarcinoma has an FGFR2 fusion, so this test helps confirm whether Lyrfigtu is right for you.
How Do I Take Lyrfigtu?
The typical starting dose of Lyrfigtu is 70 mg; you take it by mouth once a day, with or without food. You'll keep taking it until your cancer advances or side effects become too hard to manage. Swallow the capsules whole. Don't open, break, or chew them.
If you miss a dose, take it as soon as you remember, as long as it's within four hours of your usual time. If more than four hours have passed, skip that dose and take your next dose at the regular scheduled time. If you vomit after taking Lyrfigtu, don't take an extra dose. Just wait and take your next dose as scheduled.
Your health care provider may lower your dose over time if you have side effects that are hard to manage; they may also pause treatment temporarily until a side effect improves. Never adjust your own dose or stop taking Lyrfigtu without talking with your health care provider first.
Because Lyrfigtu can affect your eyes, you'll have a thorough eye exam, including a detailed imaging test of the retina, before you start treatment. You'll need repeat eye exams roughly every two months for the first 13 months, and every four months after that. Seek urgent care any time you notice new vision changes.
Lyrfigtu can harm a fetus. If you can become pregnant, your health care provider will confirm that you are not pregnant before treatment begins. You must use effective birth control during treatment and for six months after your last dose. If you can get your partner pregnant, effective birth control is recommended during treatment and for three months after the last dose. Tell your health care provider right away if you are or might be pregnant. Don't breastfeed during treatment with Lyrfigtu or for one week after your last dose.
Tell your health care provider and pharmacist about every medicine, supplement, and vitamin you take. Some medicines can change how much Lyrfigtu is in your body, which is covered in more detail in this article on Lyrfigtu interactions.
How Was Lyrfigtu Studied for Cholangiocarcinoma?
Lyrfigtu's approval is based on REFOCUS, an ongoing international study that enrolled adults with bile duct cancer whose tumors had an FGFR2 fusion or other rearrangement. Everyone in this part of the study had already been treated with at least one round of chemotherapy or chemoimmunotherapy, but none had previously taken a different FGFR inhibitor medicine.
REFOCUS included 116 people with cholangiocarcinoma. At the start of the study, participants were, on average, in their late 50s (median age, 57 ; range, 29-81), and about 6 in 10 were women. Most (96%) had the most common form of bile duct cancer, which starts inside the liver. About 9 in 10 participants had an FGFR2 fusion in which the gene joined with another gene in a way that kept the working part of FGFR2 intact; the rest had other types of FGFR2 rearrangements. Everyone had already received at least one platinum-based chemotherapy regimen.
This was a single-group study, meaning everyone received Lyrgzu, and there was no comparison group taking a placebo or a different medicine. That means the study could show whether tumors shrank, but not whether Lyrfigtu helped people live longer compared with another treatment.
What Are the Main Benefits of Lyrfigtu Based on Studies?
Researchers mainly aimed to find out how many people's tumors shrank in response to treatment, an outcome called the objective response rate.
In REFOCUS, 46% of participants had their tumor shrink enough to count as a response. A small number (about 3%) had their tumor disappear completely on scans, and more people (about 43%) had a partial shrinkage. Among people who responded, the shrinkage lasted a median of 11.8 months, and for more than 6 in 10 of them, the response lasted at least six months.
Your results may differ from what was seen in clinical studies.
Are There Additional Potential Benefits of Lyrfigtu?
Researchers also tracked how long people went without their cancer getting worse, and how long they lived overall while being treated. In an analysis of the same 116-person study group, the typical (median) time without cancer progression was about 11.3 months, and about half of participants were still progression-free at 12 months. The typical overall survival time was about 22.8 months, and about three-quarters of participants were still alive at 12 months. Nearly all participants (97%) had their disease at least stabilize, meaning it didn't grow during the study.
These are additional findings from the same trial, not the study's main measure of success, so take them as a general picture rather than a guarantee. Your results may differ from what was seen in this study.
How Long Until I See Results From Lyrfigtu?
Among people who responded to treatment in REFOCUS, the typical time to see a response on scans was about 1.9 months, though for some people it took longer, up to about 11 months. Your health care provider will likely order imaging scans periodically to track how your cancer is responding.
What Are Other Unique Considerations to Be Aware Of?
Lyrfigtu stays in your system for about 23 hours on average (its half-life is about 23 hours), and it takes about four days of daily dosing to build up to a steady level in your blood. This is why it's important to take it consistently, at around the same time each day.
Lyrfigtu can also make your skin more sensitive to sunlight. It's a good idea to wear sunscreen, protective clothing, and sunglasses and to limit direct sun exposure while you're on treatment.
How Can I Get Lyrfigtu? Is Cost Assistance Available?
Lyrfigtu requires a prescription, and your care team will coordinate getting it to a pharmacy that can dispense it. Because Lyrfigtu is newly approved, ask your health care provider's office or your insurance plan about coverage, and ask your pharmacist or Elevar Therapeutics (Lyrfigtu's drugmaker) whether a copay assistance or patient support program is available for people with or without insurance. You can find the drugmaker's contact information on the Elevar Therapeutics website.
